Roche Among EU Fast-Track Hopefuls With Lymphoma Bispecific Mosunetuzumab

 
• By Neena Brizmohun

Two companies are set to learn whether the European Medicines Agency will agree that their planned EU marketing applications merit an accelerated assessment.

The EMA can review marketing applications faster under its accelerated assessment mechanism • Source: Alamy

More from Europe

More from Geography